Literature DB >> 11867523

Epstein-Barr virus RNA confers resistance to interferon-alpha-induced apoptosis in Burkitt's lymphoma.

Asuka Nanbo1, Kaori Inoue, Kumi Adachi-Takasawa, Kenzo Takada.   

Abstract

We investigated whether Epstein--Barr virus (EBV) infection could counteract the antitumor effect of interferon (IFN)-alpha. EBV-negative subclones isolated from EBV-positive Burkitt's lymphoma (BL) cell lines Akata, Daudi and Mutu were found to fall into apoptosis after IFN-alpha treatment. On the other hand, EBV-positive counterparts exhibited striking resistance against IFN-alpha-induced apoptosis. Transfection of an individual EBV latent gene into EBV-negative BL cells revealed that EBV-encoded poly(A)(-) RNAs (EBERs) were responsible for IFN resistance. EBERs bound double-stranded (ds) RNA-activated protein kinase (PKR), a key mediator of the antiviral effect of IFN-alpha, and inhibited its phosphorylation. Transfection of dominant-negative PKR, which was catalytically inactive and could block phosphorylation of endogenous PKR, made EBV-negative BL cells resistant to IFN-alpha-induced apoptosis. Furthermore, EBERs did not bind mutant PKR, which was catalytically active but lacked dsRNA-binding activity, nor did they inhibit its phosphorylation. These results indicate that EBERs confer resistance to IFN-alpha-induced apoptosis via binding to PKR and inhibition of its phosphorylation. This is the first report that the virus counteracts IFN-induced apoptosis in virus-associated tumors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11867523      PMCID: PMC125896          DOI: 10.1093/emboj/21.5.954

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  41 in total

1.  Arsenic-interferon-alpha-triggered apoptosis in HTLV-I transformed cells is associated with tax down-regulation and reversal of NF-kappa B activation.

Authors:  M E El-Sabban; R Nasr; G Dbaibo; O Hermine; N Abboushi; F Quignon; J C Ameisen; F Bex; H de Thé; A Bazarbachi
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

2.  Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines.

Authors:  E Klein; G Klein; J S Nadkarni; J J Nadkarni; H Wigzell; P Clifford
Journal:  Cancer Res       Date:  1968-07       Impact factor: 12.701

3.  DNA sequence and expression of the B95-8 Epstein-Barr virus genome.

Authors:  R Baer; A T Bankier; M D Biggin; P L Deininger; P J Farrell; T J Gibson; G Hatfull; G S Hudson; S C Satchwell; C Séguin
Journal:  Nature       Date:  1984 Jul 19-25       Impact factor: 49.962

4.  Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines.

Authors:  K Takada
Journal:  Int J Cancer       Date:  1984-01-15       Impact factor: 7.396

5.  Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.

Authors:  S Alas; C Emmanouilides; B Bonavida
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

6.  Regulation of Epstein-Barr virus infection by recombinant interferons. Selected sensitivity to interferon-gamma.

Authors:  M Lotz; C D Tsoukas; S Fong; D A Carson; J H Vaughan
Journal:  Eur J Immunol       Date:  1985-05       Impact factor: 5.532

7.  Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction.

Authors:  N Kitagawa; M Goto; K Kurozumi; S Maruo; M Fukayama; T Naoe; M Yasukawa; K Hino; T Suzuki; S Todo; K Takada
Journal:  EMBO J       Date:  2000-12-15       Impact factor: 11.598

8.  Malignant transformation of B lymphoma cell line BJAB by Epstein-Barr virus-encoded small RNAs.

Authors:  N Yamamoto; T Takizawa; Y Iwanaga; N Shimizu; N Yamamoto
Journal:  FEBS Lett       Date:  2000-11-03       Impact factor: 4.124

9.  The Epstein-Barr virus (EBV) small RNA EBER1 binds and relocalizes ribosomal protein L22 in EBV-infected human B lymphocytes.

Authors:  D P Toczyski; A G Matera; D C Ward; J A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

10.  Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus.

Authors:  M R Lerner; N C Andrews; G Miller; J A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  1981-02       Impact factor: 11.205

View more
  100 in total

1.  Inhibition of the protein kinase PKR by the internal ribosome entry site of hepatitis C virus genomic RNA.

Authors:  Jashmin Vyas; Androulla Elia; Michael J Clemens
Journal:  RNA       Date:  2003-07       Impact factor: 4.942

2.  The lytic phase of epstein-barr virus requires a viral genome with 5-methylcytosine residues in CpG sites.

Authors:  Markus Kalla; Christine Göbel; Wolfgang Hammerschmidt
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

Review 3.  Noncoding RNPs of viral origin.

Authors:  Joan Steitz; Sumit Borah; Demian Cazalla; Victor Fok; Robin Lytle; Rachel Mitton-Fry; Kasandra Riley; Tasleem Samji
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-03-01       Impact factor: 10.005

Review 4.  EBV Noncoding RNAs.

Authors:  Rebecca L Skalsky; Bryan R Cullen
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

5.  EB virus-encoded RNAs are recognized by RIG-I and activate signaling to induce type I IFN.

Authors:  Mrinal Samanta; Dai Iwakiri; Teru Kanda; Tadaatsu Imaizumi; Kenzo Takada
Journal:  EMBO J       Date:  2006-08-31       Impact factor: 11.598

6.  NcRNA-microchip analysis: a novel approach to identify differential expression of noncoding RNAs.

Authors:  Roland Hutzinger; Jan Mrázek; Sonja Vorwerk; Alexander Hüttenhofer
Journal:  RNA Biol       Date:  2010-09-01       Impact factor: 4.652

7.  Critical role of Epstein-Barr Virus (EBV)-encoded RNA in efficient EBV-induced B-lymphocyte growth transformation.

Authors:  Misako Yajima; Teru Kanda; Kenzo Takada
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

Review 8.  The role of Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  Chi Man Tsang; Sai Wah Tsao
Journal:  Virol Sin       Date:  2015-04-21       Impact factor: 4.327

9.  Epstein-Barr virus BZLF1 gene, a switch from latency to lytic infection, is expressed as an immediate-early gene after primary infection of B lymphocytes.

Authors:  Wangrong Wen; Dai Iwakiri; Koji Yamamoto; Seiji Maruo; Teru Kanda; Kenzo Takada
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

Review 10.  Immune escape by Epstein-Barr virus associated malignancies.

Authors:  Christian Münz; Ann Moormann
Journal:  Semin Cancer Biol       Date:  2008-10-19       Impact factor: 15.707

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.